On February 2nd, Aide Technology (920180.BJ) commenced its subscription period, setting an issue price of 7.67 yuan per share. The maximum subscription limit is 1.3288 million shares, with an industry price-to-earnings ratio of 14.98 times. The listing is on the Beijing Stock Exchange, and Deppon Securities is its sponsor.
According to the prospectus, Aide Technology is primarily engaged in the research and development, production, and sales of medical devices, mainly focusing on orthopedic consumables. Its key products include spinal, trauma, and sports medicine orthopedic medical consumables, as well as wound repair products for healing injuries.
The company adheres to clinical orthopedic needs as its guiding principle, striving to become a leading domestic provider of comprehensive orthopedic surgical solutions with a product matrix covering the entire orthopedic field.
Having deeply cultivated the orthopedic medical device industry for over a decade, the company consistently focuses on end-user clinical demands, offering integrated comprehensive surgical solutions based on clinical pain points.
Initially, following the principle of minimizing iatrogenic injury in surgical treatment and fully considering the group attributes of elderly patients with chronic orthopedic diseases, the company provided minimally invasive treatment solutions including vertebroplasty, percutaneous endoscopic lumbar discectomy, and minimally invasive reduction with external fixation for non-open fractures.
Subsequently, alongside the aging population and changes in the spectrum of orthopedic diseases, the company used various surgical indications as a focus to gradually develop a product matrix suitable for clinical indications across the entire orthopedic field.
Currently, the company's products comprehensively cover the four major orthopedic areas of spine, trauma, joint, and sports medicine, as well as the wound repair field used for post-operative wound healing.
As of the signing date of the prospectus, the company and its subsidiaries collectively possess 132 product filings or registration certificates, including 62 Class I product filings, 34 Class II product registration certificates, 35 Class III product registration certificates, and 1 authorized imported medical device product.
According to data from Yixiehui, in 2023, the company ranked third among domestic medical device manufacturers for spinal vertebroplasty systems and sixth among domestic manufacturers of spinal internal implantation medical devices.
As one of the early entrants into the domestic orthopedic market, Aide Technology has always maintained the mission of providing high-quality, accessible, and affordable products, focusing on deployments in grassroots healthcare markets.
The company is dedicated to promoting the widespread application of cost-effective orthopedic medical devices, allowing high-quality medical products and services to benefit broader regions and populations.
After years of development and refinement, the company's main products have gained a strong reputation among its customer base, establishing considerable brand influence and a leading position in the field of spinal minimally invasive clinical treatment.
The company has successively received honors such as "Suzhou Municipal Enterprise Technology Center," "High-Tech Enterprise," and "Jiangsu Province Specialized, Refined, Unique, and New SME." Its Vertebroplasty Surgery System and External Fixator products have both been awarded the "Suzhou Famous Brand Product" honor.
According to the prospectus, after the raised funds (net of issuance expenses) are received, they will be invested in the following projects.
Financially, for the years 2022, 2023, 2024, and the period from January to June 2025, the company achieved operating revenues of approximately 286 million yuan, 262 million yuan, 275 million yuan, and 149 million yuan, respectively.
During the same periods, it recorded net profits of approximately 93.3894 million yuan, 63.5686 million yuan, 66.7902 million yuan, and 38.2230 million yuan, respectively.